Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alnylam, Genzyme expand their RNAi therapies alliance, Genzyme invests $700mm; deal restructured

Executive Summary

Vastly expanding on and replacing a 2012 alliance surrounding RNAi therapies for transthyretin-mediated amyloidosis (ATTR), Alnylam Pharmaceuticals Inc. and Sanofi’s Genzyme Corp. signed a new agreement for the development of RNAi treatments for genetic diseases. Genzyme gains additional rights and becomes a major Alnylam shareholder.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies